NCT07241039
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07241039
Title A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
START Midwest /ID# 272505 RECRUITING Grand Rapids Michigan 49546 United States Details
Carolina BioOncology Institute /ID# 272380 RECRUITING Huntersville North Carolina 28078 United States Details
Next Oncology - Irving /ID# 276659 RECRUITING Irving Texas 75039 United States Details
Kansai Medical University Hospital /ID# 276586 RECRUITING Hirakata-shi Osaka 573-1191 Japan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field